Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Mehr anzeigen
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...
SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session...
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...
SEATTLE, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the anti-cancer activity of...
SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.069 | -7.3482428115 | 0.939 | 0.939 | 0.8215 | 983862 | 0.85605234 | CS |
| 4 | -0.14 | -13.8613861386 | 1.01 | 1.08 | 0.8215 | 837513 | 0.93360522 | CS |
| 12 | -0.56 | -39.1608391608 | 1.43 | 1.66 | 0.8215 | 870296 | 1.15704511 | CS |
| 26 | -0.49 | -36.0294117647 | 1.36 | 1.66 | 0.8215 | 693436 | 1.26101215 | CS |
| 52 | 0.0359 | 4.30404028294 | 0.8341 | 2.31 | 0.7744 | 1016095 | 1.41986896 | CS |
| 156 | -0.42 | -32.5581395349 | 1.29 | 2.31 | 0.5 | 911907 | 1.18617644 | CS |
| 260 | -0.67 | -43.5064935065 | 1.54 | 9.8 | 0.5 | 3569566 | 3.15030584 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
